Clinical Trial Calendar

Results Date
Company Name
Zynerba Pharmaceuticals, Inc.
Top line results from phase II study of ZYN002 (BELIEVE 1 study)
Developmental And Epileptic Encephalopathies (DEE)
after Q1 2019
Pfizer Inc.
Early data from phase IB clinical trial for mini-dystrophin gene therapy candidate, PF-06939926
Duchenne muscular dystrophy (DMD) in boys
Q1 2019
Heat Biologics Inc.
Filing of IND for PTX-35
Non Small Cell Lung Cancer (NSCLC)
Karyopharm Therapeutics Inc.
Top-line data from phase III study of Selinexor in combination with Velcade and dexamethasone (SVd) (BOSTON)
Multiple myeloma who have had one to three prior lines of therapy
Q1 2019
EPIX Pharmaceuticals, Inc.
Filing of IND for next-generation Aniten compound
Metastatic castrate resistant prostate cancer
Early 2019
Retrophin Inc.
Results from phase II proof-of-concept study of CNSA-001
Phenylketonuria (PKU)
after Q1 2019
BioXcel Therapeutics, Inc.
Preliminary readouts from phase II trials of BXCL701
Rare form of prostate cancer and for treatment of pancreatic cancer
Early 2019
CohBar, Inc.
Activity readout from Phase 1a/1b clinical trial of CB4211
Nonalcoholic steatohepatitis (NASH) and obesity
after Q1 2019
MacroGenics Inc.
Top line progression-free survival data from pivotal phase III study of Margetuximab plus chemotherapy vs Trastuzumab plus chemotherapy (SOPHIA)
Relapsed/refractory HER2-positive metastatic breast cancer
Xencor Inc
Initial data from Phase 1 study of XmAb13676
B-cell malignancies
Xencor Inc
Initial data from Phase 1 study of XmAb18087
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)
Xencor Inc
Filing of IND for XmAb24306
Multiple oncology indications
after Q1 2019
Provectus Pharmaceuticals Inc.
Phase 1b data from phase 1b/2 study of intralesional PV-10 in combination with KEYTRUDA
Metastatic melanoma
after Q1 2019
Arcus Biosciences, Inc
Data from three Phase 1/1b trials of AB928 in combination with AB122 or chemotherapy
Q1 2019
Catalyst Pharmaceutical Partners Inc.
Top-line results from phase III trial of Firdapse
Congenital myasthenic syndromes
after Q1 2019
Ra Pharmaceuticals, Inc.
Data from phase II clinical trial of RA101495 SC
Generalized myasthenia gravis (gMG)
Q1 2019
Tracon Pharmaceuticals, Inc.
Interim analysis results from Phase 3 pivotal TAPPAS trial of TRC105
Viking Therapeutics, Inc.
Filing of IND for VK0214
X-linked adrenoleukodystrophy (X-ALD)
after Q1 2019
BeyondSpring Inc.
Submission of NDA for Plinabulin
Non-small cell lung cancer (NSCLC)
after Q1 2019
Novus Therapeutics, Inc.
Top line data from phase I study of OP-02
Otitis media with effusion in children
after Q1 2019
Novus Therapeutics, Inc.
Top line data from phase I study of OP-02
Acute otitis media in adults
after Q1 2019
Therapix Biosciences Ltd.
Top-line results from phase IIa, sponsor-initiated trial of THX-110
Obstructive Sleep Apnea
ProQR Therapeutics
Full data from phase I/II clinical trial of QR-110
Leber congenital amaurosis 10
after Q1 2019
Savara Inc
Top-line results from phase 2a clinical study of Molgradex (OPTIMA)
Persistent pulmonary NTM infection
Q1 2019
Tonix Pharmaceuticals Holding Corp.
Top line results from full Phase 3 HONOR study of Tonmya or TNX-102 SL(HONOR)
Posttraumatic stress disorder (PTSD)